A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

L

LyphoMed

Status

Completed

Conditions

Pneumonia, Pneumocystis Carinii
HIV Infections

Treatments

Drug: Pentamidine isethionate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002292
88-001
023B

Details and patient eligibility

About

To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Previous history of adverse reaction to pentamidine.
  • History of asthma.
  • Pulmonary Kaposi's sarcoma.

Patients with the following are excluded:

  • Previous history of adverse reaction to pentamidine.
  • History of asthma.
  • Pulmonary Kaposi's sarcoma.
  • Inability to understand the consent procedure.

All patients hospitalized at Cedars-Sinai Medical Center with AIDS and possible Pneumocystis carinii pneumonia (PCP) will be eligible.

Patients with HIV antibody or AIDS and a clinical presentation suggesting PCP are eligible.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems